Gross-to-net complexity, channel rebates, and a regulatory floor under every accounting decision.
Pharma businesses live inside the gross-to-net problem — rebates, chargebacks, discounts, and returns that can move recognized revenue by 50%+. Specialty pharmacy, 340B, GPO contracts, and state-level pricing requirements add layers most accounting teams haven’t navigated. The finance function has to be both a chief accountant and a commercial economist.
Sub-Sectors We Work In
Rebate accruals, chargeback reconciliation, channel discount accounting, and the analytics that turn gross revenue into defensible net revenue.
Customer profitability, channel mix, GPO contract economics, and the commercial reporting your sponsor expects to see.
DSCSA, 340B, state pricing transparency, and the regulatory reporting infrastructure your auditors and authorities require.
Interim CFO and Controller seats, audit readiness, and the back-office discipline most platforms need post-acquisition.
Channel inventory tracking, returns reserves, write-down discipline, and 13-week cash forecasts tied to operational drivers.
Sell-side readiness, quality of earnings, normalized gross-to-net, and the data room your bankers need to maximize the next transaction.
Gross-to-net analytics, channel profitability, and the sponsor cadence a pharma platform needs.
Gross-to-net accruals. Inventory valuation. Multi-entity consolidation. Audit readiness.
Unifying ERP, distribution chargebacks, and 867 data into channel-level dashboards.
Document intelligence on GPO and payer contracts, AI agents for rebate validation and chargeback reconciliation.
Tell us where the friction lives in your pharmaceutical portfolio company and we’ll scope a solution that fits the way the business actually runs.
CONNECT WITH US